Thrombopoietin Receptor Agonists: A New Immune Modulatory Strategy in ITP?

In 2008, new drugs that mimic the effects of thrombopoietin became available for the treatment of primary immune thrombocytopenia, e.g., romiplostim and eltrombopag. These drugs activate the thrombopoietin receptor, stimulate the production of megakaryocytes, and increase the production of platelets. Important clinical observation has been gained, such as unexpected long-term remission after stopping thrombopoietin receptor agonists. The pathophysiology of this unforeseen cure is currently the subject of discussion and is investigated in clinical trials and laboratory research projects.
Source: Seminars in Hematology - Category: Hematology Authors: Tags: April 2016 Suppl 1 ICIS Source Type: research